Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities

Interactive on-demand CCO Webcast featuring expert discussion on how new and emerging data in the management of atopic dermatitis will affect clinical practice

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: November 5, 2020 Expired: November 4, 2021

Introduction

Management of Moderate to Severe Atopic Dermatitis With Current Agents

Investigational Agents for the Treatment of Atopic Dermatitis

Targeted Monoclonal Antibodies for AD: Beyond Dupilumab

Questions and Answers

A review on how new and emerging data in the management of atopic dermatitis will affect clinical practice: atopic dermatitis conference coverage from CCO

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Expert-authored commentary on investigational selective JAK inhibitors in atopic dermatitis treatment from Clinical Care Options (CCO)

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Efficacy, safety of baricitinib in patients with moderate to severe atopic dermatitis in BREEZE-AD5: atopic dermatitis conference coverage from CCO